File(s) not publicly available
Highly Active Antiretroviral Therapy: Pharmacoeconomic issues in the management of HIV infection
journal contribution
posted on 2023-05-17, 09:29 authored by Sendi, P, Andrew PalmerAndrew Palmer, Gafni, A, Battegay, MThe advent of highly active antiretroviral therapy (HAART), including protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors, for the treatment of HIV infection has led to a dramatic decline of morbidity and mortality. The acquisition costs of HAART are substantial. However, these costs are partially offset by reduced inpatient care for opportunistic infections and other AIDS-related diseases. Furthermore, job productivity in patients infected with HIV is increased under HAART. In developed countries with a low unemployment rate, the discounted value of savings caused by increased productivity in earlier years exceeds the discounted value of later increases in costs resulting from morbidity. Therefore, HAART represents a very efficient treatment strategy that leads to overall cost savings when taking a societal perspective.
History
Publication title
PharmacoeconomicsVolume
19Issue
7Pagination
709-713ISSN
1170-7690Department/School
Menzies Institute for Medical ResearchPublisher
Adis International LtdPlace of publication
41 Centorian Dr, Private Bag 65901, Mairangi Bay, Auckland, New Zealand, 10Repository Status
- Restricted